Elanco Animal Health Incorporated (ELAN) Current Ratio
- Current ratio · latest quarter: Value 2.05×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.05× | Current assets / current liabilities. $3.80B ÷ $1.85B ≈ 2.05× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 3.80B USD | Assets, Current |
| Current obligations | 1.85B USD | Liabilities, Current |
| Cash and equivalents | 530.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.08B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 1.77B USD | Inventory, Net |
| Payables | 427.00M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.80B | $1.85B | $530.00M | (m) | $1.08B | $1.77B | $427.00M | (m) | 2.05× |
| 2026-03-31 | $3.58B | $1.66B | $428.00M | (m) | $1.08B | $1.72B | $372.00M | (m) | 2.16× |
| 2025-12-31 | $3.46B | $1.60B | $545.00M | (m) | $873.00M | $1.74B | $368.00M | (m) | 2.17× |
| 2025-09-30 | $3.49B | $1.46B | $505.00M | (m) | $894.00M | $1.71B | $352.00M | (m) | 2.40× |
| 2025-06-30 | $3.61B | $1.39B | $539.00M | (m) | $989.00M | $1.67B | $368.00M | (m) | 2.60× |
| 2025-03-31 | $3.44B | $1.27B | $487.00M | (m) | $970.00M | $1.59B | $330.00M | $44.00M | 2.71× |
| 2024-12-31 | $3.21B | $1.31B | $468.00M | (m) | $805.00M | $1.57B | $296.00M | (m) | 2.44× |
| 2024-09-30 | $3.37B | $1.32B | $490.00M | (m) | $840.00M | $1.63B | $259.00M | $44.00M | 2.55× |
| 2024-06-30 | $4.01B | $1.37B | $416.00M | (m) | $999.00M | $1.61B | $291.00M | $213.00M | 2.93× |
| 2024-03-31 | $4.05B | $1.23B | $345.00M | (m) | $988.00M | $1.64B | $302.00M | $38.00M | 3.29× |
| 2023-12-31 | $3.41B | $1.24B | $352.00M | (m) | $842.00M | $1.74B | $270.00M | $38.00M | 2.75× |
| 2023-09-30 | $3.56B | $1.26B | $369.00M | (m) | $911.00M | $1.69B | $296.00M | $39.00M | 2.82× |
| 2023-06-30 | $3.65B | $1.28B | $367.00M | (m) | $1.00B | $1.69B | $354.00M | $39.00M | 2.84× |
| 2023-03-31 | $3.55B | $1.58B | $318.00M | (m) | $1.05B | $1.60B | $381.00M | $381.00M | 2.25× |
| 2022-12-31 | $3.28B | $1.70B | $345.00M | (m) | $797.00M | $1.54B | $390.00M | $388.00M | 1.93× |
| 2022-09-30 | $3.15B | $1.61B | $460.00M | (m) | $804.00M | $1.34B | $350.00M | $394.00M | 1.96× |
| 2022-06-30 | $3.31B | $1.34B | $507.00M | (m) | $916.00M | $1.33B | $386.00M | $56.00M | 2.47× |
| 2022-03-31 | $3.19B | $1.31B | $342.00M | (m) | $973.00M | $1.34B | $402.00M | $61.00M | 2.44× |
| 2021-12-31 | $3.27B | $1.65B | $638.00M | (m) | $833.00M | $1.37B | $416.00M | $294.00M | 1.99× |
| 2021-09-30 | $3.16B | $1.36B | $453.00M | (m) | $924.00M | $1.38B | $436.00M | $61.00M | 2.32× |
| 2021-06-30 | $3.43B | $1.99B | $580.00M | (m) | $1.07B | $1.45B | $506.00M | $555.00M | 1.72× |
| 2021-03-31 | $3.34B | $2.03B | $515.00M | (m) | $1.03B | $1.42B | $411.00M | $605.00M | 1.64× |
| 2020-12-31 | $3.42B | $2.08B | $495.00M | (m) | $872.00M | $1.58B | $501.00M | $555.00M | 1.65× |
| 2020-09-30 | $3.28B | $1.87B | $659.90M | (m) | $762.30M | $1.60B | $355.90M | $553.60M | 1.75× |
| 2020-06-30 | $3.19B | $835.40M | $1.39B | (m) | $543.90M | $1.07B | $242.50M | $25.90M | 3.82× |
| 2020-03-31 | $3.12B | $707.50M | $1.21B | (m) | $676.80M | $1.02B | $215.00M | $26.00M | 4.41× |
| 2019-12-31 | $2.37B | $818.50M | $334.00M | (m) | $816.90M | $1.05B | $222.60M | $24.50M | 2.90× |
| 2019-09-30 | $2.31B | $741.50M | $309.20M | (m) | $758.30M | $1.07B | $206.10M | $24.50M | 3.12× |
| 2019-06-30 | $2.38B | $777.50M | $385.10M | (m) | $757.20M | $1.05B | $242.90M | $27.10M | 3.07× |
| 2019-03-31 | $2.28B | $708.20M | $272.10M | (m) | $684.10M | $1.04B | $252.10M | $29.00M | 3.22× |
| 2018-12-31 | $2.50B | $970.70M | $474.80M | (m) | $651.80M | $1.00B | $205.20M | $29.00M | 2.58× |
| 2018-09-30 | $2.70B | $1.25B | $300.00M | (m) | $606.10M | $1.01B | $202.70M | $0.00 | 2.17× |
| 2017-12-31 | $2.12B | $643.10M | $323.40M | (m) | $567.40M | $1.06B | $203.80M | $0.00 | 3.30× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |